Evonik increases prices of pharmaceutical amino acids

 

Evonik increases prices of pharmaceutical amino acids
 
Effective immediately, Evonik Industries is increasing the prices of its pharmaceutical amino acids. The increase, of between 10 and 15 percent depending on the amino acid and its quality, applies globally to all new orders and new supply agreements. The price increase is a result of the increased costs of raw materials and energy. 
 
Evonik's French subsidiary Rexim S.A.S. having production sites in Ham, France, and Nanning, China, is the world's third-largest supplier of amino acids and amino acid derivatives in pharmaceutical quality. These are used in the pharmaceutical industry for IV solutions and production of pharmaceutical active ingredients, such as those used to treat high blood pressure and diabetes, as well as in the cosmetics and food industries.
 
Contacts
Dr. Jürgen Krauter
Communication Health & Nutrition
+49 6181 59-6847
49 6181 59-76847

Suggested Articles

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S.